New York State Common Retirement Fund decreased its position in Progyny, Inc. (NASDAQ:PGNY - Free Report) by 90.2% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 25,570 shares of the company's stock after selling 235,362 shares during the quarter. New York State Common Retirement Fund's holdings in Progyny were worth $441,000 as of its most recent SEC filing.
Other institutional investors and hedge funds also recently made changes to their positions in the company. Pacer Advisors Inc. grew its stake in shares of Progyny by 47.5% in the fourth quarter. Pacer Advisors Inc. now owns 3,676,200 shares of the company's stock valued at $63,414,000 after acquiring an additional 1,183,558 shares in the last quarter. State Street Corp grew its stake in Progyny by 4.5% during the third quarter. State Street Corp now owns 3,113,654 shares of the company's stock worth $52,185,000 after buying an additional 134,861 shares in the last quarter. Invenomic Capital Management LP acquired a new stake in shares of Progyny during the 3rd quarter worth approximately $29,509,000. Fort Washington Investment Advisors Inc. OH boosted its position in shares of Progyny by 90.1% during the 4th quarter. Fort Washington Investment Advisors Inc. OH now owns 1,467,780 shares of the company's stock worth $25,319,000 after acquiring an additional 695,740 shares in the last quarter. Finally, Baillie Gifford & Co. boosted its holdings in shares of Progyny by 52.2% in the 4th quarter. Baillie Gifford & Co. now owns 1,332,690 shares of the company's stock valued at $22,989,000 after purchasing an additional 456,853 shares in the last quarter. Institutional investors and hedge funds own 94.93% of the company's stock.
Insider Transactions at Progyny
In other news, CEO Peter Anevski bought 209,500 shares of the company's stock in a transaction that occurred on Monday, December 23rd. The shares were acquired at an average price of $14.48 per share, for a total transaction of $3,033,560.00. Following the completion of the acquisition, the chief executive officer now directly owns 441,463 shares in the company, valued at approximately $6,392,384.24. This represents a 90.32 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, Chairman David J. Schlanger acquired 150,000 shares of the company's stock in a transaction dated Thursday, December 26th. The stock was acquired at an average cost of $14.68 per share, for a total transaction of $2,202,000.00. Following the completion of the purchase, the chairman now directly owns 228,269 shares in the company, valued at $3,350,988.92. This trade represents a 191.65 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Corporate insiders own 12.30% of the company's stock.
Progyny Price Performance
Shares of Progyny stock traded down $0.25 during midday trading on Friday, reaching $20.80. The company had a trading volume of 1,501,046 shares, compared to its average volume of 1,567,163. The stock has a fifty day moving average price of $21.24 and a 200 day moving average price of $18.71. The firm has a market cap of $1.77 billion, a PE ratio of 35.86, a P/E/G ratio of 2.39 and a beta of 1.41. Progyny, Inc. has a fifty-two week low of $13.39 and a fifty-two week high of $38.98.
Analysts Set New Price Targets
A number of equities research analysts have recently weighed in on the stock. JPMorgan Chase & Co. raised their price target on shares of Progyny from $17.00 to $23.00 and gave the company a "neutral" rating in a research note on Tuesday, January 28th. Barclays decreased their target price on shares of Progyny from $30.00 to $17.00 and set an "overweight" rating on the stock in a research note on Thursday, November 14th. Canaccord Genuity Group raised their price objective on Progyny from $17.00 to $23.00 and gave the company a "hold" rating in a report on Friday, February 28th. Bank of America boosted their price objective on Progyny from $21.00 to $25.00 and gave the stock a "buy" rating in a research report on Tuesday, February 11th. Finally, Truist Financial reiterated a "hold" rating and issued a $19.00 target price (down from $26.00) on shares of Progyny in a research report on Wednesday, November 13th. Nine research analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. Based on data from MarketBeat.com, Progyny has a consensus rating of "Hold" and an average price target of $24.82.
Check Out Our Latest Research Report on PGNY
About Progyny
(
Free Report)
Progyny, Inc, a benefits management company, specializes in fertility and family building benefits solutions in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists.
See Also
Before you consider Progyny, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Progyny wasn't on the list.
While Progyny currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
